115066-14-3
基本信息
6-CYANO-7-NITROQUINOXALINE-2,3-DIONE 2NA
6-CYANO-7-NITROQUINOXALINE-2,3-DIONE DISODIUM
6-CYANO-7-NITROQUINOXALINE-2,3-DIONE DISODIUM SALT
CNQX
CNQX 2NA
CNQX DISODIUM
CNQX DISODIUM SALT
FG-9065
CNQX DISODIUM KAINATE/AMPA RECEPTOR
CNQX (FG-9065) (6-CYANO-7-NITROQUINO
6-CYANO-7-NITROQUINOXALINE-2,3 (1H,4H)-DIONE
6-Cyano-7-nitroquinoxaline-2,3-dione, FG-9065
2,3-Dioxo-7-nitroquinoxaline-6-carbonitrile
6-Nitro-7-cyanoquinoxaline-2,3-dione
CNOX
1,2,3,4-Tetrahydro-7-nitro-2,3-dioxo-6-quinoxalinecarbonitrile
7-Nitro-2,3-dihydroxyquinoxaline-6-carbonitrile
物理化学性质
| 熔点 | 300 °C |
| 熔点 | 300 °C |
| 沸点 | 374.31°C (rough estimate) |
| 密度 | 1.5507 (rough estimate) |
| RTECS号 | VD1520000 |
| 折射率 | 1.6590 (estimate) |
| 储存条件 | protect from light |
| 溶解度 | H2O: 10 mg/mL |
| 溶解度 | 在水中的溶解度10 mg/mL |
| 酸度系数(pKa) | 8.16±0.20(Predicted) |
| 形态 | solid |
| 形态 | 固体 |
| 颜色 | orange to red |
| 颜色 | 橙色至红色 |
| 水溶解性 | H2O: >2mg/mL (warmed) |
| 稳定性 | 在室温下密封存放 |
| CAS 数据库 | 115066-14-3(CAS DataBase Reference) |
安全数据
| 危险性符号(GHS) | ![]() GHS07 |
| 警示词 | 危险 |
| 危险性描述 | H302-H315-H319-H335 |
| 防范说明 | P261-P280a-P304+P340-P305+P351+P338-P405-P501a |
| 危险品标志 | Xi |
| 安全说明 | 22-24/25 |
| 安全说明 | S22-S24/25 |
| WGK Germany | 3 |
| WGK Germany | 3 |
| 海关编码 | 29335990 |
6-氰基-7-硝基喹喔啉-2,3-二酮价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2026/06/05 | HY-15066R | 6-氰基-7-硝基喹喔啉-2,3-二酮 CNQX (Standard) | 115066-14-3 | 5 mg | 1100元 |
| 2026/06/05 | HY-15066R | 6-氰基-7-硝基喹喔啉-2,3-二酮 CNQX (Standard) | 115066-14-3 | 10 mg | 1750元 |
| 2026/06/05 | HY-15066R | 6-氰基-7-硝基喹喔啉-2,3-二酮 CNQX (Standard) | 115066-14-3 | 25 mg | 3160元 |
常见问题列表
IC50: 0.3 μM (AMPA) and 1.5 μM (kainate receptor)
CNQX (FG9065; 2-5 μM) reversibly blocks the Schaffer collateral and mossy fibre excitatory postsynaptic potential (EPSP), while sparing the fast and slow GABA-mediated inhibition in superfusion of hippocampal slices.
CNQX (1-5 μM) produces a selective and dose-dependent reduction in the amplitude of the monosynaptic component of the DR-VRR recorded from lumbar spinal segments.
CNQX (FG9065; 2-5 μM) reversibly blocks the Schaffer collateral and mossy fibre excitatory postsynaptic potential (EPSP), while sparing the fast and slow GABA-mediated inhibition in superfusion of hippocampal slices.
CNQX (1-5 μM) produces a selective and dose-dependent reduction in the amplitude of the monosynaptic component of the DR-VRR recorded from lumbar spinal segments.
| Animal Model: | Male Wistar rats weighing 180-200 g |
| Dosage: | 0.75, 1.5, and 3 mg/kg |
| Administration: | IP; 20 min before testing |
| Result: | Decreased the number of cocaine (IV; 0.25 mg/infusion) responses in a dose-dependent manner during the first 15-min cocaine-free interval |
